Drug Trial Radar · NCT05755659
Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.
Last checked: Nov 19, 2026Latest source record: Mar 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,000
Planned (sponsor's estimate)
Start
Jul 15, 2022
Primary completion
Oct 20, 2024
Study completion Dec 20, 2024
Sponsor
- Lead sponsor
- Xijing HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 6, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety of Fosaprepitant Dimeglumine Injection for the prevention of nausea and vomiting caused by tumor chemotherapy drugs, analyze the characteristics of the applicable population and clinical medication of Fosaprepitant Dimeglumine, evaluate the risk factors that may affect the efficacy of drug use, and compare the clinical benefits of different drug use modes.
Conditions
- Neoplasms
Interventions
Fosaprepitant Dimeglumine for InjectionDrug
The specification of Fosaprepitant Dimeglumine for injection is 150 mg, and the usage and dosage is: when preventing nausea and vomiting caused by HEC, this product is used in combination with dexamethasone and 5-HT3 antagonist. The dosage of Fosaprepitant Dimeglumine for injection is 150 mg, and the infusion time is 20-30 minutes. The intravenous infusion is completed 30 minutes before the beginning of chemotherapy on the first day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of Fosaprepitant DimeglumineTime frame: 7 day
- Effectiveness of Fosaprepitant DimeglumineTime frame: 7 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Air Force Military Medical University
Xi'an, Shaanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.